GO-DS21 A Comprehensive Approach to Understanding DS Comorbidities
GO-DS21 brought together experts in genetics, neuroscience, clinical care, and data science to study comorbidities in DS across multiple levels—from genes and cells to individuals and populations. The project had delivered seven main objectives:
Mapping Health Patterns in People with DS
Over 230 individuals with DS were recruited and assessed for clinical, cognitive, and biological markers. Using electronic health records and biological samples, researchers identified age-related patterns of comorbidities and compared hormone levels to those in the general population. These findings help tailor healthcare strategies to the specific needs of people with DS.
Exploring Environmental Influences
Using mouse and rat models, the project examined how diet, stress, and exercise affect DS-related health issues. The studies revealed that stress worsens obesity and that certain genetic regions contribute to metabolic disorders. These insights are crucial for designing lifestyle-based interventions.
Investigating Key Genes
GO-DS21 focused on three genes—DYRK1A, MRAP, and NRIP1—thought to drive DS comorbidities. Overexpression of DYRK1A and MRAP was shown to cause obesity and cognitive deficits. Promising pharmacological treatments targeting DYRK1A were tested in preclinical models, paving the way for future therapies.
Identifying Biomarkers and Molecular Signatures
Researchers generated one of the most comprehensive datasets on DS to date, analyzing gene expression, proteins, metabolites, and gut microbiota from both human and animal samples. These data help identify early biomarkers and understand the biological mechanisms behind DS comorbidities.
Integrating Data with Advanced Computational Tools
The project developed innovative machine learning and network-based tools to integrate clinical and molecular data. These tools, including Cosmonet and GINCCo, allow researchers to model disease mechanisms and predict health outcomes, supporting personalized medicine approaches.
Developing New Therapies
GO-DS21 tested new compounds, including DYRK1A inhibitors, and explored gene therapy and lifestyle interventions. These strategies aim to reduce the severity of comorbidities in DS and improve quality of life.
Engaging the Community and Sharing Knowledge
A major focus of GO-DS21 was to communicate findings to people with DS, their families, clinicians, and the public. The project website received over 77,000 visits. Educational videos, brochures, and a fairytale book were created to explain the science in accessible ways. A mobile app, FoodFall, was launched to promote healthy eating. Clinical guidelines on managing obesity in DS were developed and shared with healthcare providers and patient associations.
